ACADIA Pharmaceuticals NASDAQ: ACAD is pursuing growth from its DAYBUE and NUPLAZID franchises while advancing neurological and psychiatric drug candidates and looking for external deals, CEO Catherine Owen Adams said at a UBS-hosted event.
The company recently reported quarterly revenue of $342 million, up 22% from a year earlier, Adams said. DAYBUE revenue rose 39% to $140 million, while NUPLAZID revenue increased 12% to $202 million, with most of that growth driven by volume. ACADIA raised its annual DAYBUE revenue guidance to between $505 million and $520 million.
Adams said the company had more than $970 million on its balance sheet and intended to use some of that capacity for strategic business development alongside investment in its internal pipeline.
DAYBUE expansion
ACADIA has expanded its field force to reach more community physicians treating patients with Rett syndrome, Adams said. She estimated that 65% of patients are treated in the community, where the company remains about 30% penetrated. Approximately 79% of third-quarter referrals came from community physicians, she said.
The company also introduced DAYBUE STIX, a powder formulation that can be mixed into liquids other than water and requires a smaller volume. Adams said the formulation has attracted interest from patients new to treatment and those who previously discontinued it.
Persistence on STIX has tracked similarly to the earlier formulation over a relatively short period, although patients using STIX may consume a higher proportion of their prescribed dose, Adams said. Across DAYBUE cohorts, she said, persistence was above 55% at 12 months and about 50% at two years.
Outside the U.S., ACADIA launched DAYBUE in Germany in October after receiving European approval. Adams also cited a distribution deal with Japan’s KYORIN Pharmaceutical intended to support a filing and commercialization in Japan in 2028. ACADIA expects roughly 10% of global DAYBUE sales to come from outside the U.S., she said.
NUPLAZID and patent appeal
ACADIA expanded its NUPLAZID sales force’s reach from approximately 5,000 physicians to 10,000, primarily adding community primary care physicians, Adams said. Securing initial prescriptions from those new contacts has taken longer than expected, but she said the company expects the effort’s impact to become more apparent toward the end of the year and into the following year.
Adams said ACADIA stands by a district court decision concerning NUPLAZID intellectual property that is under appeal. The three-judge appeal panel could rule within weeks or as late as the middle of the following year, she said, while noting that the timing is uncertain.
She also said the company expects NUPLAZID’s net sales to decrease beyond 2030 as a result of anticipated pricing under Inflation Reduction Act negotiations. ACADIA qualifies for a small-biotech exemption that caps decreases for the first few years, she said.
Pipeline updates
For remlifanserin in Alzheimer’s disease psychosis, Adams said ACADIA is continuing an already-enrolling Phase 3 study at the 60-milligram dose after deciding to drop the 30-milligram arm based on initial Phase 2 data. The company also plans adjustments to trial sites and training and intends to use more central raters.
ACADIA is considering a statistical analysis strategy focused on patient characteristics, including disease severity, rather than changing enrollment criteria, Adams said. The company expects to discuss the analysis plan with the Food and Drug Administration in the first half of the following year.
Phase 2 results for remlifanserin in Lewy body dementia psychosis are expected in the fourth quarter of the following year. Adams said earlier studies of pimavanserin included small Lewy body subgroups with encouraging results, but cautioned that the ongoing study would determine remlifanserin’s outcome.
ACADIA also expects Phase 2 results for ACP-211 in major depressive disorder in the second half of the following year. Adams described the oral candidate as a potential twice-weekly, at-home treatment, subject to demonstrating an appropriate efficacy and safety profile.
About ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.